157245-87-9

Basic information

• Product Name: ethyl 4-(4-broMophenoxy)butanoate
• Synonyms: ethyl 4-(4-broMophenoxy)butanoate;4-(4-broMo-phenoxy)-butyric acid ethyl ester
• CAS NO: 157245-87-9
• Molecular Formula: C₁₂H₁₅BrO₃
• Molecular Weight: 287.1497
• Mol File: 157245-87-9.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 358.7±22.0 °C(Predicted)
• Appearance: /
• Density: 1.331±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: ethyl 4-(4-broMophenoxy)butanoate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 4-(4-broMophenoxy)butanoate(157245-87-9)
• EPA Substance Registry System: ethyl 4-(4-broMophenoxy)butanoate(157245-87-9)

Safety Data

• Hazardous Substances Data: 157245-87-9(Hazardous Substances Data)

Upstream product

• 106-41-2 4-bromo-phenol 
• 2969-81-5 Ethyl 4-bromobutyrate 

Downstream Products

• 7497-87-2 1-bromo-4-(3'-bromopropoxy)benzene 
• 2364-59-2 γ-phenoxybutyric acid ethyl ester 
• 55580-07-9 4-(4-bromophenoxy)butanoic acid 
• 229005-63-4 N-(4-((N-(4,4-ethylenedioxycyclohexyl)-N-methyl)aminomethyl)phenyl)-7-(4-methylphenyl)-2,3-dihydro-1-benzoxepine-4-carboxamide 
• 229005-64-5 N-[4-[N-(4-oxycyclohexyl)-N-methylaminomethyl]phenyl]-7-(4-methylphenyl)-2,3-dihydro-1-benzoxepine-4-carboxamide 
• 229004-34-6 N-(4-(2-piperidinoethyl)phenyl)-7-(4-methylphenyl)-2,3-dihydro-1-benzoxepine-4-carboxamide 
• 229005-55-4 N-(4-((N-tetrahydrothiopyran-4-yl-N-methyl)amino-methyl)phenyl)-7-(4-methylphenyl)-2,3-dihydro-1-benzoxepine-4-carboxamide 
• 229004-30-2 7-(4-methylphenyl)-N-(4-(piperidinomethyl)phenyl)-2,3-dihydro-1-benzoxepine-4-carboxamide 
• 229005-67-8 N-(4-((N-3-hydroxypropyl-N-methyl)aminomethyl)phenyl)-7-(4-methylphenyl)-2,3-dihydro-1-benzoxepine-4-carboxamide 
• 229006-96-6 7-(4-methylphenyl)-2,3-dihydro-1-benzooxepine-4-carboxylic acid 
• 229006-94-4 7-(4-methylphenyl)-2,3,4,5-tetrahydro-1-benzooxepin-5-one 

Relevant articles and documents

Design, synthesis, and biological evaluation of 3-amino-2-oxazolidinone derivatives as potent quorum-sensing inhibitors of Pseudomonas aeruginosa PAO1

Due to the increasing resistance of Pseudomonas aeruginosa to most clinically relevant antimicrobials, it is challenging to treat bacterial infection with traditional antibiotics. Quorum sensing can regulate the production of biofilms and virulence factors which are closely related to bacterial resistance. Previously we synthesized a series of oxazolidinone compounds targeting the quorum-sensing transcriptional regulatory protein CviR and ZS-12 showed good activity against Chromobacterium violaceum CV026 quorum-sensing. In this study, eighteen 3-amino-2-oxazolidinone compounds were designed and synthesized using ZS-12 as the lead compound. We initially evaluated the inhibitory activities of novel oxazolidinone compounds against QS using C. violaceum CV026 as a reporter strain. Thirteen compounds showed good activities (IC50 range 3.69–63.58 μM) and YXL-13 inhibition was the most significant (IC50 = 3.686 ± 0.5790 μM) against biofilm formation and virulence factors determination of P. aeruginosa PAO1. In vitro, YXL-13 significantly inhibited the formation of PAO1 biofilm (range 42.98%–17.67%), the production of virulence factors (pyocyanin, elastase, rhamnolipid, and protease), and bacterial motility. Moreover, the combination of YXL-13 with an antibiotic (meropenem trihydrate) could significantly improve the antibiotic susceptibility of biofilm P. aeruginosa PAO1 cells. In vivo, YXL-13 significantly prolonged the lifespan of wildtype Caenorhabditis elegans N2 infected by P. aeruginosa PAO1. In conclusion, YXL-13 is a candidate agent for antibiotic-resistant P. aeruginosa PAO1and provides a method for finding new antibacterial drugs.

SUBSTITUTED POLYCYCLIC ANTIBACTERIAL COMPOUNDS

The present description relates to substituted polycyclic compounds of Formula (I), Formula (II) or Formula (III): wherein the dashed line represents an optional double bond and Rl, R2, R4, R5, R7, X and Z are as defined herein, and forms and compositions thereof, and also relates to uses of a compound of Formula (I), Formula (II) or Formula (III) or a form thereof and methods for treating or ameliorating Neisseria gonorrhoeae (N. gonorrhoeae) in a subject in need thereof comprising, administering an effective amount of the compound to the subject.

Synthesis of oxadiazole-morpholine derivatives and manifestation of the repressed CD31 Microvessel Density (MVD) as tumoral angiogenic parameters in Dalton's Lymphoma

A series of oxadiazole derivatives possessing morpholine 6a-l were synthesized by nucleophilic substitution reaction of key intermediates [1,3,4]-oxadiazole-2-thiol derivatives 5a-l with 4-(2-chloroethyl) morpholine. Compounds 6a-l were evaluated for their in vitro and in vivo antitumor potential in Dalton's Lymphoma Ascites (DLA) tumor cells. Among 6a-l series, compound 6a with concentration ～8.5 μM have shown extensive cytotoxicity in vitro and 85% reduction in tumor volume in vivo, attributing an excellent anti-proliferative capability towards the cancer cells. Compound 6a has extensively inhibited the Microvessel Density (MVD) or tumoral neovasculature which was evident from the CD31 immuno staining and peritoneal H&E staining. The major reason for the antiproliferative activity of compound 6a was due to the repression of tumor vasculature.